(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders - 2You finally got a doctor's appointment. Here's how to get the most out of it
- 3The Way to Business: Startup Illustrations Learned
- 4EU delegation urges China to tighten export controls
- 5EU-funded BioSupPack project turns brewery waste into bioplastics
- German hauliers warn soaring energy prices may soon impact consumers
- Kennedy approves adding two rare disorders to newborn screenings
- Find Serenity: 10 Stunning Setting up camp Areas
- Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- Investigating the World's Chief Authentic Urban communities to Visit
- 7 Delightful Ferris Wheels, Do You Like Them?
- Poland identifies two Ukrainian suspects in railway sabotage blast
- Step by step instructions to Explore the Close to home Consequence of Cellular breakdown in the lungs
